The table below shows Allogene Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
-
$0.00
$0.00
$0.00
$0.00
$0.00
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$32.00M
$31.16M
$40.16M
$50.20M
$44.71M
$50.35M
SG&A
ALLO annual revenue (10-K history)
Allogene Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $22.00K in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.